Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

448 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Reproducibility and Accuracy of the PRIMARY Score on PSMA PET and of PI-RADS on Multiparametric MRI for Prostate Cancer Diagnosis Within a Real-World Database.
Emmett L, Papa N, Counter W, Calais J, Barbato F, Burger I, Eiber M, Roberts MJ, Agrawal S, Franklin A, Xue A, Rasiah K, John N, Moon D, Frydenberg M, Yaxley J, Stricker P, Wong K, Coughlin G, Gianduzzo T, Kua B, Ho B, Nguyen A, Liu V, Lee J, Hsiao E, Sutherland T, Perry E, Fendler WP, Hope TA. Emmett L, et al. Among authors: john n. J Nucl Med. 2024 Jan 2;65(1):94-99. doi: 10.2967/jnumed.123.266164. J Nucl Med. 2024. PMID: 38050155
177Lu-PSMA SPECT Quantitation at 6 Weeks (Dose 2) Predicts Short Progression-Free Survival for Patients Undergoing 177Lu-PSMA-I&T Therapy.
John N, Pathmanandavel S, Crumbaker M, Counter W, Ho B, Yam AO, Wilson P, Niman R, Ayers M, Poole A, Hickey A, Agrawal S, Perkins G, Kallinen A, Eslick E, Stockler MR, Joshua AM, Nguyen A, Emmett L. John N, et al. J Nucl Med. 2023 Mar;64(3):410-415. doi: 10.2967/jnumed.122.264677. Epub 2022 Sep 8. J Nucl Med. 2023. PMID: 36215568 Free article.
Patient outcomes following a response biomarker-guided approach to treatment using 177Lu-PSMA-I&T in men with metastatic castrate-resistant prostate cancer (Re-SPECT).
Emmett L, John N, Pathmanandavel S, Counter W, Ayers M, Sharma S, Agrawal S, Poole A, Hovey E, Pranavan G, Gedye C, Mallesara G, Guminski A, Lee A, Stockler MR, Hickey A, Eu P, Joshua AM, Crumbaker M, Nguyen A. Emmett L, et al. Among authors: john n. Ther Adv Med Oncol. 2023 Mar 1;15:17588359231156392. doi: 10.1177/17588359231156392. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 36872949 Free PMC article.
Development of a Visually Calculated SUVmean (HIT Score) on Screening PSMA PET/CT to Predict Treatment Response to 177Lu-PSMA Therapy: Comparison with Quantitative SUVmean and Patient Outcomes.
Swiha M, Papa N, Sabahi Z, Ayati N, John N, Pathmanandavel S, Crumbaker M, Li S, Agrawal S, Ayers M, Hickey A, Sharma S, Nguyen A, Emmett L. Swiha M, et al. Among authors: john n. J Nucl Med. 2024 Apr 18:jnumed.123.267014. doi: 10.2967/jnumed.123.267014. Online ahead of print. J Nucl Med. 2024. PMID: 38637137
The Canadian VirusSeq Data Portal & Duotang: open resources for SARS-CoV-2 viral sequences and genomic epidemiology.
Gill EE, Jia B, Murall CL, Poujol R, Anwar MZ, John NS, Richardsson J, Hobb A, Olabode AS, Lepsa A, Duggan AT, Tyler AD, N'Guessan A, Kachru A, Chan B, Yoshida C, Yung CK, Bujold D, Andric D, Su E, Griffiths EJ, Domselaar GV, Jolly GW, Ward HKE, Feher H, Baker J, Simpson JT, Uddin J, Ragoussis J, Eubank J, Fritz JH, Gálvez JH, Fang K, Cullion K, Rivera L, Xiang L, Croxen MA, Shiell M, Prystajecky N, Quirion PO, Bajari R, Rich S, Mubareka S, Moreira S, Cain S, Sutcliffe SG, Kraemer SA, Joly Y, Alturmessov Y, Consortium C, Consortium C, Academic VDP, Network H, Fiume M, Snutch TP, Bell C, Lopez-Correa C, Hussin JG, Joy JB, Colijn C, Gordon PMK, Hsiao WWL, Poon AFY, Knox NC, Courtot M, Stein L, Otto SP, Bourque G, Shapiro BJ, Brinkman FSL. Gill EE, et al. Among authors: john ns. ArXiv [Preprint]. 2024 May 8:arXiv:2405.04734v1. ArXiv. 2024. PMID: 38764594 Free PMC article. Preprint.
Beyond PI-RADS: Combining MRI PI-RADS and PSMA-PET/CT PRIMARY Score in a Composite (P) Score for More Accurate Diagnosis of Clinically Significant Prostate Cancer.
Emmett L, Papa N, Hope TA, Fendler W, Calais J, Burger I, Eiber M, Barbato F, Moon D, Counter W, John N, Xue A, Franklin A, Thompson J, Rasiah K, Frydenberg M, Yaxley J, Buteau J, Agrawal S, Ho B, Nguyen A, Liu V, Lee J, Woo H, Hsiao E, Sutherland T, Perry E, Stricker P, Hofman MS, Kasivisvanathan V, Roberts M, Murphy D. Emmett L, et al. Among authors: john n. J Urol. 2024 May 17:101097JU0000000000004010. doi: 10.1097/JU.0000000000004010. Online ahead of print. J Urol. 2024. PMID: 38758680
Oral corticosteroid dosage and taper duration at onset in myelin oligodendrocyte glycoprotein antibody-associated disease influences time to first relapse.
Trewin BP, Dale RC, Qiu J, Chu M, Jeyakumar N, Dela Cruz F, Andersen J, Siriratnam P, Ma KKM, Hardy TA, van der Walt A, Lechner-Scott J, Butzkueven H, Broadley SA, Barnett MH, Reddel SW, Brilot F, Kalincik T, Ramanathan S; Australasian MOGAD Study Group. Trewin BP, et al. J Neurol Neurosurg Psychiatry. 2024 May 16:jnnp-2024-333463. doi: 10.1136/jnnp-2024-333463. Online ahead of print. J Neurol Neurosurg Psychiatry. 2024. PMID: 38744459 Free article.
CD8+ T cell targeting of tumor antigens presented by HLA-E.
Iyer RF, Verweij MC, Nair SS, Morrow D, Mansouri M, Chakravarty D, Beechwood T, Meyer C, Uebelhoer L, Lauron EJ, Selseth A, John N, Thin TH, Dzedzik S, Havenar-Daughton C, Axthelm MK, Douglas J, Korman A, Bhardwaj N, Tewari AK, Hansen S, Malouli D, Picker LJ, Früh K. Iyer RF, et al. Among authors: john n. Sci Adv. 2024 May 10;10(19):eadm7515. doi: 10.1126/sciadv.adm7515. Epub 2024 May 10. Sci Adv. 2024. PMID: 38728394 Free PMC article.
448 results